Archive · 26 Sep 2025
Reader Reactions: US Pharma Tariffs, Digital Security & Policy
Readers discussed changes to digital payment security with new two-step authentication.
The US imposed tariffs on pharma if production is not in America.
The new rules can change the legal status of the Adani issue.
Low interest rates by RBI led to the dangers of a liquidity trap.
GST 2.0 is expected to help consumption.
Readers are providing feedback on the economic and regulatory changes.
RBI to enforce two-step authentication for digital payments from April 2026.
US President Trump imposed a 100% tariff on certain pharmaceuticals from October 1, 2025.
Indian pharma majors are impacted by US tariff policies.
Low interest rates raise concerns about a liquidity trap due to lack of private investment.
GST 2.0 provided a push for consumption.
- Who
- Readers of The Hindu Business Line
- What
- Discuss RBI policies, US tariffs, and economic conditions.
- When
- Published September 26, 2025.
- Where
- India.
- Why
- To provide feedback and opinions on current economic and regulatory issues.
- Digital Payment Security
- Two-step authentication mandatory by April 2026
- Cyber Theft Cost
- Nearly ₹23,000 crore last year
- US Pharma Tariff
- 100% on branded pharmaceuticals from October 1, 2025, if production not in US
- Indian Pharma Production
- World's largest producer of generic drugs; supplies nearly 20% of global demand
- RBI Action
- Kept interest rates low
- GST 2.0 Impact
- Provided a push for consumption